135 related articles for article (PubMed ID: 30707908)
21. The TRPS1 transcription factor: androgenic regulation in prostate cancer and high expression in breast cancer.
Chang GT; Jhamai M; van Weerden WM; Jenster G; Brinkmann AO
Endocr Relat Cancer; 2004 Dec; 11(4):815-22. PubMed ID: 15613454
[TBL] [Abstract][Full Text] [Related]
22. Differential regulation of PTEN expression by androgen receptor in prostate and breast cancers.
Wang Y; Romigh T; He X; Tan MH; Orloff MS; Silverman RH; Heston WD; Eng C
Oncogene; 2011 Oct; 30(42):4327-38. PubMed ID: 21532617
[TBL] [Abstract][Full Text] [Related]
23. Conjugated and non-conjugated androgens differentially modulate specific early gene transcription in breast cancer in a cell-specific manner.
Notas G; Pelekanou V; Castanas E; Kampa M
Steroids; 2010; 75(8-9):611-8. PubMed ID: 19857505
[TBL] [Abstract][Full Text] [Related]
24. hZIP1 zinc uptake transporter down regulation and zinc depletion in prostate cancer.
Franklin RB; Feng P; Milon B; Desouki MM; Singh KK; Kajdacsy-Balla A; Bagasra O; Costello LC
Mol Cancer; 2005 Sep; 4():32. PubMed ID: 16153295
[TBL] [Abstract][Full Text] [Related]
25. Androgens regulate follicle stage-dependent pro- and anti-apoptosis in teleost ovaries through ZIP9 activation of different G proteins†.
Converse A; Thomas P
Biol Reprod; 2019 Aug; 101(2):377-391. PubMed ID: 31074766
[TBL] [Abstract][Full Text] [Related]
26. Membrane-initiated steroid action in breast and prostate cancer.
Kampa M; Pelekanou V; Castanas E
Steroids; 2008 Oct; 73(9-10):953-60. PubMed ID: 18249430
[TBL] [Abstract][Full Text] [Related]
27. Identification of novel androgen receptor target genes in prostate cancer.
Jariwala U; Prescott J; Jia L; Barski A; Pregizer S; Cogan JP; Arasheben A; Tilley WD; Scher HI; Gerald WL; Buchanan G; Coetzee GA; Frenkel B
Mol Cancer; 2007 Jun; 6():39. PubMed ID: 17553165
[TBL] [Abstract][Full Text] [Related]
28. Differentially expressed genes in the prostate cancer cell line LNCaP after exposure to androgen and anti-androgen.
Coutinho-Camillo CM; Salaorni S; Sarkis AS; Nagai MA
Cancer Genet Cytogenet; 2006 Apr; 166(2):130-8. PubMed ID: 16631469
[TBL] [Abstract][Full Text] [Related]
29. CCAAT/enhancer-binding protein delta: a molecular target of 1,25-dihydroxyvitamin D3 in androgen-responsive prostate cancer LNCaP cells.
Ikezoe T; Gery S; Yin D; O'Kelly J; Binderup L; Lemp N; Taguchi H; Koeffler HP
Cancer Res; 2005 Jun; 65(11):4762-8. PubMed ID: 15930295
[TBL] [Abstract][Full Text] [Related]
30. A novel human G protein-coupled receptor is over-expressed in prostate cancer.
Parmigiani RB; Magalhães GS; Galante PA; Manzini CV; Camargo AA; Malnic B
Genet Mol Res; 2004 Dec; 3(4):521-31. PubMed ID: 15688318
[TBL] [Abstract][Full Text] [Related]
31. Testosterone/bicalutamide antagonism at the predicted extracellular androgen binding site of ZIP9.
Bulldan A; Malviya VN; Upmanyu N; Konrad L; Scheiner-Bobis G
Biochim Biophys Acta Mol Cell Res; 2017 Dec; 1864(12):2402-2414. PubMed ID: 28943399
[TBL] [Abstract][Full Text] [Related]
32. Transcriptional regulation of the androgen signaling pathway by the Wilms' tumor suppressor gene WT1.
Zaia A; Fraizer GC; Piantanelli L; Saunders GF
Anticancer Res; 2001; 21(1A):1-10. PubMed ID: 11299720
[TBL] [Abstract][Full Text] [Related]
33. Estrogen and Androgen Hormone Levels Modulate the Expression of PIWI Interacting RNA in Prostate and Breast Cancer.
Öner Ç; Turgut Coşan D; Çolak E
PLoS One; 2016; 11(7):e0159044. PubMed ID: 27414029
[TBL] [Abstract][Full Text] [Related]
34. Relaxin drives Wnt signaling through upregulation of PCDHY in prostate cancer.
Thompson VC; Hurtado-Coll A; Turbin D; Fazli L; Lehman ML; Gleave ME; Nelson CC
Prostate; 2010 Jul; 70(10):1134-45. PubMed ID: 20503398
[TBL] [Abstract][Full Text] [Related]
35. HOXC8 inhibits androgen receptor signaling in human prostate cancer cells by inhibiting SRC-3 recruitment to direct androgen target genes.
Axlund SD; Lambert JR; Nordeen SK
Mol Cancer Res; 2010 Dec; 8(12):1643-55. PubMed ID: 21047772
[TBL] [Abstract][Full Text] [Related]
36. Regulator of G-protein signaling 2 (RGS2) inhibits androgen-independent activation of androgen receptor in prostate cancer cells.
Cao X; Qin J; Xie Y; Khan O; Dowd F; Scofield M; Lin MF; Tu Y
Oncogene; 2006 Jun; 25(26):3719-34. PubMed ID: 16449965
[TBL] [Abstract][Full Text] [Related]
37. Epidermal growth factor receptor-dependent stimulation of amphiregulin expression in androgen-stimulated human prostate cancer cells.
Sehgal I; Bailey J; Hitzemann K; Pittelkow MR; Maihle NJ
Mol Biol Cell; 1994 Mar; 5(3):339-47. PubMed ID: 8049525
[TBL] [Abstract][Full Text] [Related]
38. The activation of OR51E1 causes growth suppression of human prostate cancer cells.
Maßberg D; Jovancevic N; Offermann A; Simon A; Baniahmad A; Perner S; Pungsrinont T; Luko K; Philippou S; Ubrig B; Heiland M; Weber L; Altmüller J; Becker C; Gisselmann G; Gelis L; Hatt H
Oncotarget; 2016 Jul; 7(30):48231-48249. PubMed ID: 27374083
[TBL] [Abstract][Full Text] [Related]
39. Androgens and estrogens stimulate ribosome biogenesis in prostate and breast cancer cells in receptor dependent manner.
Ray S; Johnston R; Campbell DC; Nugent S; McDade SS; Waugh D; Panov KI
Gene; 2013 Aug; 526(1):46-53. PubMed ID: 23608168
[TBL] [Abstract][Full Text] [Related]
40. Bringing androgens up a NOTCH in breast cancer.
Tarulli GA; Butler LM; Tilley WD; Hickey TE
Endocr Relat Cancer; 2014 Aug; 21(4):T183-202. PubMed ID: 25001242
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
